Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Fritz Schröder

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Geographic Areas

Living Beings

Mice

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Roobol Monique J; Schröder Fritz H; Crawford E David; Freedland Stephen J; Sartor A Oliver; Fleshner Neil; Andriole Gerald L
A framework for the identification of men at increased risk for prostate cancer.
Schröder Fritz H
PSA screening--a review of recent studies.
Schröder Fritz H; van Weerden Wytske M
Prostate cancer--chemoprevention.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Fritz Schröder (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Roobol Monique J; Schröder Fritz H; Crawford E David; Freedland Stephen J; Sartor A Oliver; Fleshner Neil; Andriole Gerald L
A framework for the identification of men at increased risk for prostate cancer.
The Journal of urology 2009;182(5):2112-20.
2009: Schröder Fritz H
PSA screening--a review of recent studies.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():402-4.
2009: Schröder Fritz H; van Weerden Wytske M
Prostate cancer--chemoprevention.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():355-9.
2009: van den Bergh Roderick C N; Essink-Bot Marie-Louise; Roobol Monique J; Wolters Tineke; Schröder Fritz H; Bangma Chris H; Steyerberg Ewout W
Anxiety and distress during active surveillance for early prostate cancer.
Cancer 2009;115(17):3868-78.
2009: van den Bergh Roderick C N; Roemeling Stijn; Roobol Monique J; Aus Gunnar; Hugosson Jonas; Rannikko Antti S; Tammela Teuvo L; Bangma Chris H; Schröder Fritz H
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
BJU international 2009;103(11):1472-7.
2009: Schröder Fritz H; Roobol Monique J
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Current opinion in urology 2009;19(3):227-31.
2009: Schröder Fritz H; Hugosson Jonas; Roobol Monique J; Tammela Teuvo L J; Ciatto Stefano; Nelen Vera; Kwiatkowski Maciej; Lujan Marcos; Lilja Hans; Zappa Marco; Denis Louis J; Recker Franz; Berenguer Antonio; Määttänen Liisa; Bangma Chris H; Aus Gunnar; Villers Arnauld; Rebillard Xavier; van der Kwast Theodorus; Blijenberg Bert G; Moss Sue M; de Koning Harry J; Auvinen Anssi;
Screening and prostate-cancer mortality in a randomized European study.
The New England journal of medicine 2009;360(13):1320-8.
2009: Schröder Fritz H; Bangma Chris H; Wolff Johannes M; Alcaraz Antonio; Montorsi Francesco; Mongiat-Artus Pierre; Abrahamsson Per-Anders; McNicholas Tom A; Castro Ramiro S; Nandy Indrani M
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
BJU international 2009;103(5):590-6.
2009: Jansen Flip H; Roobol Monique; Jenster Guido; Schröder Fritz H; Bangma Chris H
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
European urology 2009;55(3):563-74.
2009: Korfage Ida J; Pluijm Saskia; Roobol Monique; Dohle Gert R; Schröder Fritz H; Essink-Bot Marie-Louise
Erectile dysfunction and mental health in a general population of older men.
The journal of sexual medicine 2009;6(2):505-12.
2009: Wolters Tineke; Roobol Monique J; Bangma Chris H; Schröder Fritz H
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
European urology 2009;55(2):385-92.
2009: Schröder Fritz H; Roobol Monique J
Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
BJU international 2009;103(2):143-4.
2009: Schröder Fritz H
Review of diagnostic markers for prostate cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2009;181():173-82.
2009: van den Bergh Roderick Cn; Wolters Tineke; Spaander Manon Cw; Schröder Fritz H; van Leenders Geert Jlh
Non-prostatic pathology on prostate needle-biopsy - colorectal carcinoid: a case report.
Cases journal 2009;2(1):75.
2008: van den Bergh Roderick C N; Roobol Monique J; Wolters Tineke; van Leeuwen Pim J; Schröder Fritz H
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
BJU international 2008;102(9):1068-73.
2008: Schröder Fritz H
Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Urologic oncology 2008;26(5):533-41.
2008: van den Bergh Roderick C N; Roemeling Stijn; Roobol Monique J; Wolters Tineke; Schröder Fritz H; Bangma Chris H
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
European urology 2008;54(3):505-16.
2008: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; Schröder Fritz H
The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
European urology 2008;54(3):581-8.
2008: Korfage Ida J; Roobol Monique; de Koning Harry J; Kirkels Wim J; Schröder Fritz H; Essink-Bot Marie-Louise
Does "normal" aging imply urinary, bowel, and erectile dysfunction? A general population survey.
Urology 2008;72(1):3-9.
2008: Gosselaar C; Kranse R; Roobol M J; Roemeling S; Schröder F H
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.
The Prostate 2008;68(9):985-93.
2008: Schröder Fritz H
Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.
European urology 2008;53(6):1129-37.
2008: Schröder Fritz H; Bangma Chris H; Roobol Monique J
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
European urology 2008;53(5):901-8.
2008: Roemeling Stijn; Schröder Fritz H
Words of wisdom. Re: Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.
European urology 2008;53(3):663-4.
2008: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; Wolters Tineke; van Leenders Geert J L H; Schröder Fritz H
The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
BJU international 2008;101(6):685-90.
2008: Schröder Fritz H; Carter H Ballentine; Wolters Tineke; van den Bergh Roderick C N; Gosselaar Claartje; Bangma Chris H; Roobol Monique J
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
European urology 2008;53(3):468-77.
2008: Wolters Tineke; Roobol Monique J; Schröder Fritz H; van der Kwast Theodorus H; Roemeling Stijn; van der Cruijsen-Koeter Ingrid W; Bangma Chris H; van Leenders Geert J L H;
Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
BJU international 2008;101(3):283-8.
2008: van Weerden Wytske M; Schröder Fritz H
The use of PSA as biomarker in nutritional intervention studies of prostate cancer.
Chemico-biological interactions 2008;171(2):204-11.
2008: Vis André N; Roemeling Stijn; Reedijk Ardine M J; Otto Suzie J; Schröder Fritz H
Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.
European urology 2008;53(1):91-8.
2007: van den Bergh Roderick C N; Roemeling Stijn; Roobol Monique J; Roobol Wouter; Schröder Fritz H; Bangma Chris H
Prospective validation of active surveillance in prostate cancer: the PRIAS study.
European urology 2007;52(6):1560-3.
2007: Boormans Joost L; Schröder Fritz H
Re: Prostate cancer progression and survival in BRCA2 mutation carriers.
European urology 2007;52(5):1529.
2007: Roemeling Stijn; Roobol Monique J; Kattan Michael W; van der Kwast Theo H; Steyerberg Ewout W; Schröder Fritz H
Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.
Cancer 2007;110(10):2218-21.
2007: Raaijmakers René; de Vries Stijn H; Blijenberg Bert G; Wildhagen Mark F; Postma Renske; Bangma Chris H; Darte Claude; Schröder Fritz H
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
European urology 2007;52(5):1358-64.
2007: Schröder F H
Words of wisdom. Re: Statin drugs and risk of advanced prostate cancer (PC).
European urology 2007;52(4):1258-9.
2007: Schröder Fritz H
Words of wisdom. Re: detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
European urology 2007;52(3):922.
2007: Schröder Fritz H; Roobol Monique J
Words of wisdom. Re: prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
European urology 2007;52(3):921.
2007: Roobol Monique J; Grenabo Anna; Schröder Fritz H; Hugosson Jonas
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Journal of the National Cancer Institute 2007;99(17):1296-303.
2007: Roemeling Stijn; Roobol Monique J; Otto Suzie J; Habbema Dik F; Gosselaar Claartje; Lous Jan J; Cuzick Jack; Schröder Fritz H
Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.
The Prostate 2007;67(10):1053-60.
2007: Postma Renske; Schröder Fritz H; van Leenders Geert J L H; Hoedemaeker Robert F; Vis Andre N; Roobol Monique J; van der Kwast Theodorus H
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
European urology 2007;52(1):89-97.
2007: Schröder Fritz H
Re: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
European urology 2007;51(5):1443-4.
2007: Roemeling Stijn; Roobol Monique J; de Vries Stijn H; Wolters Tineke; Gosselaar Claartje; van Leenders Geert J L H; Schröder Fritz H
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
European urology 2007;51(5):1244-50; discussion 1251.
2007: Korfage Ida J; de Koning Harry J; Habbema J Dik F; Schröder Fritz H; Essink-Bot Marie-Louise
Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls?
BJU international 2007;99(4):801-6.
2007: Vis André N; Roemeling Stijn; Kranse Ries; Schröder Fritz H; van der Kwast Theo H
Should we replace the Gleason score with the amount of high-grade prostate cancer?
European urology 2007;51(4):931-9.
2007: Schröder Fritz H
Early versus delayed endocrine therapy for prostate cancer.
Endocrine-related cancer 2007;14(1):1-11.
2007: Bangma C H; Roemeling S; Schröder F H
Overdiagnosis and overtreatment of early detected prostate cancer.
World journal of urology 2007;25(1):3-9.
2007: Schröder Fritz H; Habbema Dik F; Roobol Monique J; Bangma Chris H
Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction.
European urology 2007;51(3):588-90.
2007: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; van der Kwast Theo H; Schröder Fritz H
Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
The Prostate 2007;67(2):154-61.
2007: de Vries Stijn H; Postma Renske; Raaijmakers René; Roemeling Stijn; Otto Suzie; de Koning Harry J; Schröder Fritz H
Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
European urology 2007;51(2):366-74; discussion 374.
2007: Steyerberg E W; Roobol M J; Kattan M W; van der Kwast T H; de Koning H J; Schröder F H
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
The Journal of urology 2007;177(1):107-12; discussion 112.
2006: Schröder Fritz H
The role of PSA in secondary screening of the same population.
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 2006;78(4):147-8.
2006: Roemeling Stijn; Kranse Ries; Vis André N; Gosselaar Claartje; van der Kwast Theo H; Schröder Fritz H
Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
Cancer 2006;107(12):2779-85.
2006: Draisma Gerrit; Postma Renske; Schröder Fritz H; van der Kwast Theo H; de Koning Harry J
Gleason score, age and screening: modeling dedifferentiation in prostate cancer.
International journal of cancer. Journal international du cancer 2006;119(10):2366-71.
2006: van der Cruijsen-Koeter Ingrid W; Roobol Monique J; Wildhagen Mark F; van der Kwast T H; Kirkels W J; Schröder Fritz H
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
Urology 2006;68(3):615-20.
2006: Otto Suzie J; Schröder Fritz H; de Koning Harry J
Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4184-9.
2006: Roemeling Stijn; Roobol Monique J; Postma Renske; Gosselaar Claartje; van der Kwast Theo H; Bangma Chris H; Schröder Fritz H
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
European urology 2006;50(3):475-82.
2006: Schröder Fritz H; Albertsen Peter
Open to debate. The motion: there is evidence that prostate cancer screening does more good than harm.
European urology 2006;50(2):377-80.
2006: Vis André N; Schröder Fritz H; van der Kwast Theodorus H
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
European urology 2006;50(2):258-65.
2006: Roemeling Stijn; Roobol Monique J; Gosselaar Claartje; Schröder Fritz H
Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
The Prostate 2006;66(10):1076-81.
2006: Postma Renske; van Leenders Arno G J L H; Roobol Monique J; Schröder Fritz H; van der Kwast Theodorus H
Tumour features in the control and screening arm of a randomized trial of prostate cancer.
European urology 2006;50(1):70-5.
2006: Limpens Jacqueline; Schröder Fritz H; de Ridder Corrina M A; Bolder Cindy A; Wildhagen Mark F; Obermüller-Jevic Ute C; Krämer Klaus; van Weerden Wytske M
Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice.
The Journal of nutrition 2006;136(5):1287-93.
2006: Roobol Monique J; Schröder Fritz H; Kranse Ries;
A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
The Prostate 2006;66(6):604-12.
2006: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; de Vries Stijn H; Cruijsen-Koeter Ingrid van der; van der Kwast Theo H; Schröder Fritz H;
Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
The Prostate 2006;66(6):625-31.
2006: van der Kwast Theodorus H; Ciatto Stefano; Martikainen Paula M; Hoedemaeker Robert; Laurila Marita; Pihl Carl-Gustaph; Hugosson Jonas; Neetens Ingrid; Nelen Vera; Di Lollo Simonetta; Roobol Monique J; Määtänen Liisa; Santonja Carlos; Moss Sue; Schröder Fritz H
Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.
International journal of cancer. Journal international du cancer 2006;118(10):2538-42.
2006: Korfage I J; Essink-Bot M-L; Janssens A C J W; Schröder F H; de Koning H J
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up.
British journal of cancer 2006;94(8):1093-8.
2006: Roemeling Stijn; Roobol Monique J; de Vries Stijn H; Gosselaar Claartje; van der Kwast Theo H; Schröder Fritz H
Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.
The Journal of urology 2006;175(4):1332-6.
2006: Postma Renske; van Marion Ronald; van Duin Mark; Vissers Kees J; Wink Josiane C; Schröder Fritz H; Tanke Hans J; Szuhai Karoly; van der Kwast Theo H; van Dekken Herman
Array-based genomic analysis of screen-detected Gleason score 6 and 7 prostatic adenocarcinomas.
Anticancer research 2006;26(2A):1193-200.
2006: Schröder Fritz H; Roobol Monique J; van der Kwast Theo H; Kranse Ries; Bangma Chris H
Does PSA velocity predict prostate cancer in pre-screened populations?
European urology 2006;49(3):460-5; discussion 465.
2006: Roemeling Stijn; Schröder Fritz H
Prostate cancer: risks and benefits of screening.
Nature clinical practice. Urology 2006;3(1):4-5.
2006: Korfage Ida J; de Koning Harry J; Roobol Monique; Schröder Fritz H; Essink-Bot Marie-Louise
Prostate cancer diagnosis: the impact on patients' mental health.
European journal of cancer (Oxford, England : 1990) 2006;42(2):165-70.
2006: Roemeling S; van Leenders G J L H; Schröder F H
Very late local recurrence after surgery for prostate cancer unaccompanied by detectable PSA levels.
Prostate cancer and prostatic diseases 2006;9(2):192-4.
2005: Schröder Fritz H; Roobol Monique J; Boevé Egbert R; de Mutsert Reneé; Zuijdgeest-van Leeuwen Sonja D; Kersten I; Wildhagen Mark F; van Helvoort Ardy
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
European urology 2005;48(6):922-30; discussion 930-1.
2005: van Duin Mark; van Marion Ronald; Vissers Kees; Watson J E Vivienne; van Weerden Wytske M; Schröder Fritz H; Hop Wim C J; van der Kwast Theo H; Collins Colin; van Dekken Herman
High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.
Genes, chromosomes & cancer 2005;44(4):438-49.
2005: van Gils M P M Q; Stenman U H; Schalken J A; Schröder F H; Luider T M; Lilja H; Bjartell A; Hamdy F C; Pettersson K S I; Bischoff R; Takalo H; Nilsson O; Mulders P F A; Bangma C H
Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
European urology 2005;48(6):1031-41.
2005: Schröder Fritz H; Raaijmakers René; Postma Renske; van der Kwast Theo H; Roobol Monique J
4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
The Journal of urology 2005;174(2):489-94; discussion 493-4.
2005: Korfage Ida J; Essink-Bot Marie-Louise; Borsboom Gerard J J M; Madalinska Joanna B; Kirkels Wim J; Habbema J Dik F; Schröder Fritz H; de Koning Harry J
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer.
International journal of cancer. Journal international du cancer 2005;116(2):291-6.
2005: van der Cruijsen-Koeter Ingrid W; Vis André N; Roobol Monique J; Wildhagen Mark F; de Koning Harry J; van der Kwast Theo H; Schröder Fritz H
Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
The Journal of urology 2005;174(1):121-5.
2005: Van der Kwast Th H; Postma R; Hoedemaeker R F; van Leenders G J L H; Schröder F H
Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
The Canadian journal of urology 2005;12 Suppl 2():16-20.
2005: de Vries Stijn H; Raaijmakers René; Blijenberg Bert G; Mikolajczyk Stephan D; Rittenhouse Harry G; Schröder F H
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
Urology 2005;65(5):926-30.
2005: Schröder Fritz H; Roobol Monique J; Damhuis Ronald A M; de Koning Harry J; Blijenberg Bert G; Van der Kwast Theo H; Kirkels Wim J; Bangma Chris H
Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.
Journal of the National Cancer Institute 2005;97(9):696.
2005: Postma R; Schröder F H; van der Kwast T H
Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
Urology 2005;65(4):745-9.
2005: Postma R; Schröder F H
Screening for prostate cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(6):825-33.
2005: Schröder Fritz H
Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
The Canadian journal of urology 2005;12 Suppl 1():2-6; discussion 92-3.
2005: Roobol Monique J; Roobol Dina W; Schröder Fritz H
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Urology 2005;65(2):343-6.
2005: Gosselaar Claartje; Roobol Monique J; Schröder Fritz H
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
BJU international 2005;95(2):231-7.
2005: Postma Rensbe; de Vries Shijn H; Roobol Monique J; Wildhagen Mark F; Schröder Fritz H; van der Kwast Theo H
Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Cancer 2005;103(4):708-16.
2005: Kranse Ries; Dagnelie Pieter C; van Kemenade Monique C; de Jong Frank H; Blom Jan H M; Tijburg Lilian B M; Weststrate Jan A; Schröder Fritz H
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study.
International journal of cancer. Journal international du cancer 2005;113(5):835-40.
2004: de Vries Stijn H; Raaijmakers René; Kranse Ries; Blijenberg Bert G; Schröder F H
Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.
The Journal of urology 2004;172(6 Pt 1):2193-6.
2004: Postma Renske; Roobol Monique; Schröder Fritz H; van der Kwast Theodorus H
Lesions predictive for prostate cancer in a screened population: first and second screening round findings.
The Prostate 2004;61(3):260-6.
2004: Schröder Fritz H; Kurth Karl Heinz; Fosså Sophie D; Hoekstra Wytze; Karthaus Peter P M; Debois Muriel; Collette Laurence;
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
The Journal of urology 2004;172(3):923-7.
2004: Raaijmakers Rene; Blijenberg Bert G; Finlay Judith A; Rittenhouse Harry G; Wildhagen Mark F; Roobol Monique J; Schröder Fritz H
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
The Journal of urology 2004;171(6 Pt 1):2245-9.
2004: Roobol M J; van der Cruijsen I W; Schröder F H
No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Urology 2004;63(5):892-7; discussion 897-9.
2004: Limpens Jacqueline; van Weerden Wytske M; Krämer Klaus; Pallapies Dirk; Obermüller-Jevic Ute C; Schröder Fritz H
Re: Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets.
Journal of the National Cancer Institute 2004;96(7):554; author reply 554-5.
2004: Bangma C H; Wildhagen M F; Yurdakul G; Schröder F H; Blijenberg B G
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
BJU international 2004;93(6):720-4.
2004: Schröder Fritz H; Whelan Peter; de Reijke Theo M; Kurth Karl Heinz; Pavone-Macaluso Michele; Mattelaer Johan; van Velthoven Roland F; Debois Muriel; Collette Laurence;
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
European urology 2004;45(4):457-64.
2004: Postma Renske; Roobol Monique; Schröder Fritz H; van der Kwast Theodorus H
Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Cancer 2004;100(5):968-75.
2004: van Dekken Herman; Paris Pamela L; Albertson Donna G; Alers Janneke C; Andaya Armann; Kowbel David; van der Kwast Theodorus H; Pinkel Daniel; Schröder Fritz H; Vissers Kees J; Wildhagen Mark F; Collins Colin
Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis.
Genes, chromosomes & cancer 2004;39(3):249-56.
2004: Raaijmakers René; Wildhagen Mark F; Ito Kazuto; Pàez Alvaro; de Vries Stijn H; Roobol Monique J; Schröder Fritz H
Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Urology 2004;63(2):316-20.
2004: Roobol M J; Kranse R; de Koning H J; Schröder F H
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Urology 2004;63(2):309-13; discussion 313-5.
2004: Otto S J; Schröder F H; de Koning H J
Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?
Journal of medical screening 2004;11(2):89-92.
2003: Hoedemaeker R F; Van der Kwast T H; Schröder F H
The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.
BJU international 2003;92 Suppl 2():92-6.
2003: Roobol M J; Kirkels W J; Schröder F H
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).
BJU international 2003;92 Suppl 2():48-54.
2003: Schröder F H; Denis L J; Roobol M; Nelen V; Auvinen A; Tammela T; Villers A; Rebillard X; Ciatto S; Zappa M; Berenguer A; Paez A; Hugosson J; Lodding P; Recker F; Kwiatkowski M; Kirkels W J;
The story of the European Randomized Study of Screening for Prostate Cancer.
BJU international 2003;92 Suppl 2():1-13.
2003: Schröder F H; de Vries S H; Bangma C H
Watchful waiting in prostate cancer: review and policy proposals.
BJU international 2003;92(8):851-9.
2003: van der Cruijsen-Koeter Ingrid W; van der Kwast T H; Schröder Fritz H
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.
Journal of the National Cancer Institute 2003;95(19):1462-6.
2003: Schepers Marieke S J; Duim Ronald A J; Asselman Marino; Romijn Johannes C; Schröder Fritz H; Verkoelen Carl F
Internalization of calcium oxalate crystals by renal tubular cells: a nephron segment-specific process?
Kidney international 2003;64(2):493-500.
2003: Draisma Gerrit; Boer Rob; Otto Suzie J; van der Cruijsen Ingrid W; Damhuis Ronald A M; Schröder Fritz H; de Koning Harry J
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
Journal of the National Cancer Institute 2003;95(12):868-78.
2003: van Dekken Herman; Alers Janneke C; Damen Irma A A J; Vissers Kees J; Krijtenburg Pieter-Jaap; Hoedemaeker Robert F; Wildhagen Mark F; Hop Wim C J; van der Kwast Theodorus H; Tanke Hans J; Schröder Fritz H
Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors.
Laboratory investigation; a journal of technical methods and pathology 2003;83(6):789-96.
2003: Otto Suzie J; van der Cruijsen Ingrid W; Liem Michael K; Korfage Ida J; Lous Jan J; Schröder Fritz H; de Koning Harry J
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
International journal of cancer. Journal international du cancer 2003;105(3):394-9.
2003: Schröder Fritz H
Screening for prostate cancer.
The Urologic clinics of North America 2003;30(2):239-51, viii.
2003: Paris Pamela L; Albertson Donna G; Alers Janneke C; Andaya Armann; Carroll Peter; Fridlyand Jane; Jain Ajay N; Kamkar Sherwin; Kowbel David; Krijtenburg Pieter-Jaap; Pinkel Daniel; Schröder Fritz H; Vissers Kees J; Watson Vivienne J E; Wildhagen Mark F; Collins Colin; Van Dekken Herman
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays.
The American journal of pathology 2003;162(3):763-70.
2003: Blijenberg Bert G; Wildhagen Mark F; Bangma Chris H; Finlay Judith A; Väisänen Ville; Schröder Fritz H
Comparison of two assays for human kallikrein 2.
Clinical chemistry 2003;49(2):243-7.
2003: Schepers Marieke S J; Asselman Marino; Duim Ronald A J; Romijn Johannes C; Schröder Fritz H; Verkoelen Carl F
Pericellular matrix formation by renal tubule epithelial cells in relation to crystal binding.
Nephron. Experimental nephrology 2003;94(3):e103-12.
2002: Yurdakul G; Bangma C H; Blijenberg B G; van Zelst B D; Wildhagen M F; van der Kwast Th H; Schröder F H
Different PSA assays lead to detection of prostate cancers with identical histological features.
European urology 2002;42(2):154-8.
2002: Vis A N; van Rhijn B W G; Noordzij M A; Schröder F H; van der Kwast Th H
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.
The Journal of pathology 2002;197(2):148-54.
2002: Schepers Marieke S J; van der Boom Burt G; Romijn Johannes C; Schröder Fritz H; Verkoelen Carl F
Urinary crystallization inhibitors do not prevent crystal binding.
The Journal of urology 2002;167(4):1844-7.
2002: Vis A N; Kranse R; Roobol M; van der Kwast Th H; Schröder F H
Serendipity in detecting disease in low prostate-specific antigen ranges.
BJU international 2002;89(4):384-9.
2002: Jongsma Johan; Oomen Monique H; Noordzij Marinus A; Van Weerden Wytske M; Martens Gerard J M; van der Kwast Theodorus H; Schröder Fritz H; van Steenbrugge Gert J
Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
The Prostate 2002;50(4):203-15.
2002: de Koning Harry J; Liem Michael K; Baan Caroline A; Boer Rob; Schröder Fritz H; Alexander Freda E;
Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial.
International journal of cancer. Journal international du cancer 2002;98(2):268-73.
2002: Roobol Monique J; Kranse Ries; van der Cruijsen Ingrid W; Schröder Fritz H
A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.
Urology 2002;59(1):91-6.
2002: de Koning Harry J; Auvinen Anssi; Berenguer Sanchez Antonio; Calais da Silva Fernando; Ciatto Stefano; Denis Louis; Gohagan John K; Hakama Matti; Hugosson Jonas; Kranse Ries; Nelen Vera; Prorok Philip C; Schröder Fritz H;
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
International journal of cancer. Journal international du cancer 2002;97(2):237-44.
2002: van der Drift D G F; Vroege J A; Groenendijk P M; Slob A K; Schröder F H; Mickisch G H J
The plication procedure for penile curvature: surgical outcome and postoperative sexual functioning.
Urologia internationalis 2002;69(2):120-4.
2001: Schröder F H; Wildhagen M F;
Screening for prostate cancer: evidence and perspectives.
BJU international 2001;88(8):811-7.
2001: Schröder F H
Prostate cancer: natural history and surgical treatment of localised disease.
European journal of cancer (Oxford, England : 1990) 2001;37 Suppl 7():S127-36.
2001: Blijenberg B G; Yurdakul G; Van Zelst B D; Bangma C H; Wildhagen M F; Schröder F H
Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer.
BJU international 2001;88(6):545-50.
2001: Jiménez N; Jongsma J; Calvo A; van der Kwast T H; Treston A M; Cuttitta F; Schröder F H; Montuenga L M; van Steenbrugge G J
Peptidylglycine alpha-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate.
International journal of cancer. Journal international du cancer 2001;94(1):28-34.
2001: Scheltema J M; Romijn J C; van Steenbrugge G J; Schröder F H; Mickisch G H
Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
Anticancer research 2001;21(5):3161-6.
2001: Van Der Cruijsen-Koeter I W; Wildhagen M F; De Koning H J; Schröder F H
The value of current diagnostic tests in prostate cancer screening.
BJU international 2001;88(5):458-66.
2001: Vis A N; Hoedemaeker R F; Roobol M; Schröder F H; van der Kwast T H
The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.
Cancer 2001;92(3):524-34.
2001: Hoedemaeker R F; van der Kwast T H; Boer R; de Koning H J; Roobol M; Vis A N; Schröder F H
Pathologic features of prostate cancer found at population-based screening with a four-year interval.
Journal of the National Cancer Institute 2001;93(15):1153-8.
2001: de Water R; Leenen P J; Noordermeer C; Nigg A L; Houtsmuller A B; Kok D J; Schröder F H
Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38(2):331-8.
2001: Incrocci L; Madalinska J B; Essink-Bot M L; Van Putten W L; Koper P C; Schröder F H
Sexual functioning in patients with localized prostate cancer awaiting treatment.
Journal of sex & marital therapy 2001;27(4):353-63.
2001: Vis A N; Hoedemaeker R F; Roobol M; van der Kwast T H; Schröder F H
Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
The Prostate 2001;47(4):252-61.
2001: Schröder F H
Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges.
European urology 2001;39 Suppl 4():49-53.
2001: Madalinska J B; Essink-Bot M L; de Koning H J; Kirkels W J; van der Maas P J; Schröder F H
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1619-28.
2001: Vis A N; Hoedemaeker R F; van der Kwast T H; Schröder F H
Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model.
The Prostate 2001;46(2):154-62.
2001: Madalinska J B; Essink-Bot M L; de Koning H J; Kirkels W J; van der Maas P J; Schröder F H
Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment.
The Prostate 2001;46(2):87-97.
2001: Alers J C; Krijtenburg P J; Vis A N; Hoedemaeker R F; Wildhagen M F; Hop W C; van Der Kwast T T; Schröder F H; Tanke H J; van Dekken H
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.
The American journal of pathology 2001;158(2):399-406.
2001: Schröder F H; Roobol-Bouts M; Vis A N; van der Kwast T; Kranse R
Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Urology 2001;57(1):83-90.
2001: Van Brussel J P; Jan Van Steenbrugge G; Van Krimpen C; Bogdanowicz J F; Van Der Kwast T H; Schröder F H; Mickisch G H
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
The Journal of urology 2001;165(1):130-5.
2001: Vis A N; Oomen M; Schröder F H; van der Kwast T H
Feasibility of assessment of promoter methylation of the CD44 gene in serum of prostate cancer patients.
Molecular urology 2001;5(4):199-203.
2000: Vis A N; Noordzij M A; Fitoz K; Wildhagen M F; Schröder F H; van der Kwast T H
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
The Journal of urology 2000;164(6):2156-61.
2000: Vis A N; Boerma M O; Ciatto S; Hoedemaeker R F; Schröder F H; van der Kwast T H
Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy.
Urology 2000;56(4):617-21.
2000: Beemsterboer P M; de Koning H J; Kranse R; Trienekens P H; van der Maas P J; Schröder F H
Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
The Journal of urology 2000;164(4):1216-20.
2000: Nijs H G; Essink-Bot M L; DeKoning H J; Kirkels W J; Schröder F H
Why do men refuse or attend population-based screening for prostate cancer?
Journal of public health medicine 2000;22(3):312-6.
2000: de Water R; Noordermeer C; Houtsmuller A B; Nigg A L; Stijnen T; Schröder F H; Kok D J
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;36(3):615-25.
2000: Schröder F H; Alexander F E; Bangma C H; Hugosson J; Smith D S
Screening and early detection of prostate cancer.
The Prostate 2000;44(3):255-63.
2000: Bosch J L; Klijn A J; Schröder F H; Hop W C
The artificial urinary sphincter in 86 patients with intrinsic sphincter deficiency: satisfactory actuarial adequate function rates.
European urology 2000;38(2):156-60.
2000: Hoedemaeker R F; Rietbergen J B; Kranse R; Schröder F H; van der Kwast T H
Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
The Journal of urology 2000;164(2):411-5.
2000: Schröder F H; van den Ouden D
Management of locally advanced prostate cancer. 2. Radiotherapy, neoadjuvant endocrine treatment, update 1997-1999.
World journal of urology 2000;18(3):204-15.
2000: van den Ouden D; Schröder F H
Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery.
World journal of urology 2000;18(3):194-203.
2000: Alers J C; Rochat J; Krijtenburg P J; Hop W C; Kranse R; Rosenberg C; Tanke H J; Schröder F H; van Dekken H
Identification of genetic markers for prostatic cancer progression.
Laboratory investigation; a journal of technical methods and pathology 2000;80(6):931-42.
2000: Schröder F H; van der Cruijsen-Koeter I; de Koning H J; Vis A N; Hoedemaeker R F; Kranse R
Prostate cancer detection at low prostate specific antigen.
The Journal of urology 2000;163(3):806-12.
2000: Jongsma J; Oomen M H; Noordzij M A; Van Weerden W M; Martens G J; van der Kwast T H; Schröder F H; van Steenbrugge G J
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Cancer research 2000;60(3):741-8.
2000: Schröder F H; Kranse R; Barbet N; Hop W C; Kandra A; Lassus M
Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
The Prostate 2000;42(2):107-15.
2000: Schröder F H; Collette L; de Reijke T M; Whelan P
Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
British journal of cancer 2000;82(2):283-90.
2000: Jongsma J; Oomen M H; Noordzij M A; Romijn J C; van Der Kwast T H; Schröder F H; van Steenbrugge G J
Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines.
The Prostate 2000;42(1):34-44.
2000: van Brussel J P; Busstra M B; Lang M S; Catsburg T; Schröder F H; Mickisch G H
A phase II study of temozolomide in hormone-refractory prostate cancer.
Cancer chemotherapy and pharmacology 2000;45(6):509-12.
1999: Blijenberg B G; Storm B N; Van Zelst B D; Kruger A E; Schröder F H
New developments in the standardization of total prostate-specific antigen.
Clinical biochemistry 1999;32(8):627-34.
1999: Noordzij M A; van Steenbrugge G J; Schröder F H; Van der Kwast T H
Decreased expression of CD44 in metastatic prostate cancer.
International journal of cancer. Journal international du cancer 1999;84(5):478-83.
1999: Beemsterboer P M; Kranse R; de Koning H J; Habbema J D; Schröder F H
Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).
International journal of cancer. Journal international du cancer 1999;84(4):437-41.
1999: Beemsterboer P M; de Koning H J; Birnie E; van der Maas P J; Schröder F H
Advanced prostate cancer: course, care, and cost implications.
The Prostate 1999;40(2):97-104.
1999: Kranse R; Beemsterboer P; Rietbergen J; Habbema D; Hugosson J; Schröder F H
Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).
The Prostate 1999;39(4):316-22.
1999: van Brussel J P; van Steenbrugge G J; Romijn J C; Schröder F H; Mickisch G H
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins.
European journal of cancer (Oxford, England : 1990) 1999;35(4):664-71.
1999: Verkoelen C F; Kok D J; van der Boom B G; de Jonge H R; Schröder F H; Romijn J C
LLC-PK1 cells as a model system to study proximal tubule transport of water and other compounds relevant for renal stone disease.
Urological research 1999;27(2):109-15.
1999: Verkoelen C F; van der Boom B G; Kok D J; Houtsmuller A B; Visser P; Schröder F H; Romijn J C
Cell type-specific acquired protection from crystal adherence by renal tubule cells in culture.
Kidney international 1999;55(4):1426-33.
1999: de Water R; Noordermeer C; van der Kwast T H; Nizze H; Boevé E R; Kok D J; Schröder F H
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1999;33(4):761-71.
1999: Rietbergen J B; Hoedemaeker R F; Kruger A E; Kirkels W J; Schröder F H
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.
The Journal of urology 1999;161(4):1192-8.
1999: Klijn A J; Hop W C; Schröder F H; Bosch J L
[Satisfactory long-term results with a sphincter prosthesis in patients with urinary incontinence due to an intrinsic urinary sphincter deficiency: evaluation of 86 patients]
Nederlands tijdschrift voor geneeskunde 1999;143(7):352-5.
1999: Dubbink H J; Hoedemaeker R F; van der Kwast T H; Schröder F H; Romijn J C
Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern.
Laboratory investigation; a journal of technical methods and pathology 1999;79(2):141-50.
1999: Jongsma J; Oomen M H; Noordzij M A; Van Weerden W M; Martens G J; van der Kwast T H; Schröder F H; van Steenbrugge G J
Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.
The American journal of pathology 1999;154(2):543-51.
1999: Schröder F H
Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects.
BJU international 1999;83(2):161-70.
1999: Hoedemaeker R F; Kranse R; Rietbergen J B; Kruger A E; Schröder F H; van der Kwast T H
Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.
Cancer 1999;85(1):145-52.
1999: Schröder F H
The future of endocrine treatment in early prostate cancer: concluding remarks.
European urology 1999;36 Suppl 2():27-30.
1999: Schröder F H; Kranse R; Rietbergen J; Hoedemaeke R; Kirkels W
The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam.
European urology 1999;35(5-6):539-43.
1998: Schröder F H; van der Maas P; Beemsterboer P; Kruger A B; Hoedemaeker R; Rietbergen J; Kranse R
Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Journal of the National Cancer Institute 1998;90(23):1817-23.
1998: Rietbergen J B; Kruger A E; Hoedemaeker R F; Bangma C H; Kirkels W J; Schröder F H
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer.
The Journal of urology 1998;160(6 Pt 1):2121-5.
1998: Blijenberg B G; Roobol M; Schröder F H
Analytical issues on prostate-specific antigen in relation to prostate cancer screening.
Clinical biochemistry 1998;31(8):633-9.
1998: Klijn A J; Hop W C; Mickisch G; Schröder F H; Bosch J L
The artificial urinary sphincter in men incontinent after radical prostatectomy: 5 year actuarial adequate function rates.
British journal of urology 1998;82(4):530-3.
1998: van den Ouden D; Hop W C; Schröder F H
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy.
The Journal of urology 1998;160(4):1392-7.
1998: Rietbergen J B; Kranse R; Hoedemaeker R F; Kruger A E; Bangma C H; Kirkels W J; Schröder F H
Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study.
Urology 1998;52(2):237-46.
1998: Alers J C; Krijtenburg P J; Hop W C; Bolle W A; Schröder F H; van der Kwast T H; Bosman F T; van Dekken H
Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours.
The Journal of pathology 1998;185(3):273-83.
1998: Essink-Bot M L; de Koning H J; Nijs H G; Kirkels W J; van der Maas P J; Schröder F H
Short-term effects of population-based screening for prostate cancer on health-related quality of life.
Journal of the National Cancer Institute 1998;90(12):925-31.
1998: Verkoelen C F; van der Boom B G; Houtsmuller A B; Schröder F H; Romijn J C
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture.
The American journal of physiology 1998;274(5 Pt 2):F958-65.
1998: Weijerman P C; Zhang Y; Shen J; Dubbink H J; Romijn J C; Peehl D M; Schröder F H
Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines.
Urology 1998;51(4):657-62.
1998: König J J; Teubel W; Kamst E; Romijn J C; Schröder F H; Hagemeijer A
Cytogenetic analysis of 39 prostate carcinomas and evaluation of short-term tissue culture techniques.
Cancer genetics and cytogenetics 1998;101(2):116-22.
1998: Weijerman P C; Schurmans J R; Hop W C; Schröder F H; Bosch J L
Morbidity and quality of life in patients with orthotopic and heterotopic continent urinary diversion.
Urology 1998;51(1):51-6.
1998: Rietbergen J B; Schröder F H
Screening for prostate cancer--more questions than answers.
Acta oncologica (Stockholm, Sweden) 1998;37(6):515-32.
1998: Schröder F H
Antiandrogens as monotherapy for prostate cancer.
European urology 1998;34 Suppl 3():12-7.
1998: van den Ouden D; Kranse R; Hop W C; van der Kwast T H; Schröder F H
Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma.
Urologia internationalis 1998;60(1):17-24.
1997: Weijerman P C; van Drunen E; König J J; Teubel W; Romijn J C; Schröder F H; Hagemeijer A
Specific cytogenetic aberrations in two novel human prostatic cell lines immortalized by human papillomavirus type 18 DNA.
Cancer genetics and cytogenetics 1997;99(2):108-15.
1997: Alers J C; Krijtenburg P J; Rosenberg C; Hop W C; Verkerk A M; Schröder F H; van der Kwast T H; Bosman F T; van Dekken H
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Laboratory investigation; a journal of technical methods and pathology 1997;77(5):437-48.
1997: Cao L C; Boevé E R; de Bruijn W C; Kok D J; de Water R; Deng G; Schröder F H
Glycosaminoglycans and semisynthetic sulfated polysaccharides: an overview of their potential application in treatment of patients with urolithiasis.
Urology 1997;50(2):173-83.
1997: Rietbergen J B; Kruger A E; Kranse R; Schröder F H
Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program.
Urology 1997;49(6):875-80.
1997: Bangma C H; Rietbergen J B; Kranse R; Blijenberg B G; Petterson K; Schröder F H
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
The Journal of urology 1997;157(6):2191-6.
1997: Noordzij M A; van Steenbrugge G J; Verkaik N S; Schröder F H; van der Kwast T H
The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):805-15.
1997: Rembrink K; Romijn J C; van der Kwast T H; Rübben H; Schröder F H
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer.
The Prostate 1997;31(3):168-74.
1997: Bangma C H; Kranse R; Blijenberg B G; Schröder F H
Free and total prostate-specific antigen in a screened population.
British journal of urology 1997;79(5):756-62.
1997: Bangma C H; Rietbergen J B; Schröder F H
Prostate-specific antigen as a screening test. The Netherlands experience.
The Urologic clinics of North America 1997;24(2):307-14.
1997: Rietbergen J B; Kranse R; Kirkels W J; De Koning H J; Schröder F H
Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection.
British journal of urology 1997;79 Suppl 2():57-63.
1997: Schröder F H; Norming U; Blumenstein B A; Busch C; Van Glabbeke M; Høisaeter P A; Johansson J E; Tribukait B
Phase II studies on prostate cancer.
Urology 1997;49(4A Suppl):3-14.
1997: Schröder F H; Bangma C H
The European Randomized Study of Screening for Prostate Cancer (ERSPC).
British journal of urology 1997;79 Suppl 1():68-71.
1997: van den Ouden D; Hop W C; Kranse R; Schröder F H
Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate.
British journal of urology 1997;79(2):203-11.
1997: Bangma C H; Kranse R; Blijenberg B G; Schröder F H
The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
The Journal of urology 1997;157(2):544-7.
1997: Verkaik N S; Schröder F H; Romijn J C
Clinical usefulness of RT-PCR detection of hematogenous prostate cancer spread.
Urological research 1997;25(6):373-84.
1997: Hoedemaeker R F; Rietbergen J B; Kranse R; van der Kwast T H; Schröder F H
Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.
World journal of urology 1997;15(6):339-45.
1997: Scheltema J M; Romijn J C; van Steenbrugge G J; Beck W T; Schröder F H; Mickisch G H
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.
Journal of cancer research and clinical oncology 1997;123(10):546-54.
1997: de Bruijn W C; de Water R; van Run P R; Boevé E R; Kok D J; Cao L C; Romijn H C; Verkoelen C F; Schröder F H
Ultrastructural osteopontin localization in papillary stones induced in rats.
European urology 1997;32(3):360-7.
1997: Verkoelen C F; van der Boom B G; Schröder F H; Romijn J C
Cell cultures and nephrolithiasis.
World journal of urology 1997;15(4):229-35.
1997: Nijs H G; Tordoir D M; Schuurman J H; Kirkels W J; Schröder F H
Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance.
Journal of medical screening 1997;4(2):102-6.
1997: Cao L C; Deng G; Boevé E R; Romijn J C; de Bruijn W C; Verkoelen C F; Schröder F H
Does urinary oxalate interfere with the inhibitory role of glycosaminoglycans and semisynthetic sulfated polysaccharides in calcium oxalate crystallization?
European urology 1997;31(4):485-92.
1997: Kooistra A; Romijn J C; Schröder F H
Stromal inhibition of epithelial cell growth in the prostate; overview of an experimental study.
Urological research 1997;25 Suppl 2():S97-105.
1996: van Weerden W M; de Ridder C M; Verdaasdonk C L; Romijn J C; van der Kwast T H; Schröder F H; van Steenbrugge G J
Development of seven new human prostate tumor xenograft models and their histopathological characterization.
The American journal of pathology 1996;149(3):1055-62.
1996: Noordzij M A; van Weerden W M; de Ridder C M; van der Kwast T H; Schröder F H; van Steenbrugge G J
Neuroendocrine differentiation in human prostatic tumor models.
The American journal of pathology 1996;149(3):859-71.
1996: König J J; Teubel W; Romijn J C; Schröder F H; Hagemeijer A
Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers.
Human pathology 1996;27(7):720-7.
1996: Dubbink H J; Verkaik N S; Faber P W; Trapman J; Schröder F H; Romijn J C
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.
The Biochemical journal 1996;315 ( Pt 3)():901-8.
1996: Bangma C H; Niemer A Q; Grobbee D E; Schröder F H
Transrectal ultrasonic volumetry of the prostate: in vivo comparison of different methods.
The Prostate 1996;28(2):107-10.
1996: Verkoelen C F; Romijn J C; Cao L C; Boevé E R; De Bruijn W C; Schröder F H
Crystal-cell interaction inhibition by polysaccharides.
The Journal of urology 1996;155(2):749-52.
1996: Boevé E R; Cao L C; Deng G; De Bruijn W C; Schröder F H
Effect of two new polysaccharides on growth, agglomeration and zeta potential of calcium phosphate crystals.
The Journal of urology 1996;155(1):368-73.
1996: de Water R; Boevé E R; van Miert P P; Deng G; Cao L C; Stijnen T; de Bruijn W C; Schröder F H
Experimental nephrolithiasis in rats: the effect of ethylene glycol and vitamin D3 on the induction of renal calcium oxalate crystals.
Scanning microscopy 1996;10(2):591-601; discussion 601-3.
1996: de Water R; Boevé E R; van Miert P P; Vermaire C P; van Run P R; Cao L C; de Bruijn W C; Schröder F H
Pathological and immunocytochemical changes in chronic calcium oxalate nephrolithiasis in the rat.
Scanning microscopy 1996;10(2):577-87; discussion 587-90.
1996: de Bruijn W C; de Water R; Boevé E R; van Run P R; Vermaire P J; van Miert P P; Romijn J C; Verkoelen C F; Cao L C; Schröder F H
Lectin-cytochemistry of experimental rat nephrolithiasis.
Scanning microscopy 1996;10(2):557-76.
1996: Cao L C; Deng G; Boevé E R; de Bruijn W C; de Water R; Verkoelen C F; Romijn J C; Schröder F H
Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization.
Scanning microscopy 1996;10(2):401-11; discussion 412-4.
1995: Bangma C H; Kranse R; Blijenberg B G; Schröder F H
The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.
Urology 1995;46(6):773-8.
1995: Davidson P J; Hop W; Kurth K H; Fossa S D; Waehre H; Schröder F H
Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group.
The Journal of urology 1995;154(6):2118-22.
1995: Bangma C H; Hop W C; Schröder F H
Eliminating the need for per-operative frozen section analysis of pelvic lymph nodes during radical prostatectomy.
British journal of urology 1995;76(5):595-9.
1995: Bosch J L; Hop W C; Bangma C H; Kirkels W J; Schröder F H
Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.
The Prostate 1995;27(5):241-9.
1995: Bangma C H; HOP WCJ; Schröder F H
Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.
The Journal of urology 1995;154(4):1403-6.
1995: Bentvelsen F M; Brinkmann A O; van der Schoot P; van der Linden J E; van der Kwast T H; Boersma W J; Schröder F H; Nijman J M
Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat.
Molecular and cellular endocrinology 1995;113(2):245-53.
1995: Schröder F H
Screening, early detection, and treatment of prostate cancer: a European view.
Urology 1995;46(3 Suppl A):62-70.
1995: Noordzij M A; van der Kwast T H; van Steenbrugge G J; van Weerden W M; Oomen M H; Schröder F H
Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues.
The Prostate 1995;27(3):154-9.
1995: Bentvelsen F M; Brinkmann A O; van der Linden J E; Schröder F H; Nijman J M
Decreased immunoreactive androgen receptor levels are not the cause of isolated hypospadias.
British journal of urology 1995;76(3):384-8.
1995: Bosch J L; Hop W C; Kirkels W J; Schröder F H
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community.
Urology 1995;46(3 Suppl A):34-40.
1995: Schurmans J R; Weerman P C; Bosch J L; van der Leij E M; Schröder F H
Quality of life assessment in heterotopic and orthotopic neobladder reconstruction: a comparison.
Acta urologica Belgica 1995;63(3):55-8.
1995: Kooistra A; van den Eijnden-van Raaij A J; Klaij I A; Romijn J C; Schröder F H
Stromal inhibition of prostatic epithelial cell proliferation not mediated by transforming growth factor beta.
British journal of cancer 1995;72(2):427-34.
1995: Schröder F H; Denis L J; Kirkels W; de Koning H J; Standaert B
European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies.
Cancer 1995;76(1):129-34.
1995: Bosch J L; Kranse R; van Mastrigt R; Schröder F H
Dependence of male voiding efficiency on age, bladder contractility and urethral resistance: development of a voiding efficiency nomogram.
The Journal of urology 1995;154(1):190-4.
1995: Verkoelen C F; Romijn J C; de Bruijn W C; Boevé E R; Cao L C; Schröder F H
Association of calcium oxalate monohydrate crystals with MDCK cells.
Kidney international 1995;48(1):129-38.
1995: Noordzij M A; van der Kwast T H; van Steenbrugge G J; Hop W J; Schröder F H
The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy.
International journal of cancer. Journal international du cancer 1995;62(3):252-8.
1995: Kooistra A; Elissen N M; König J J; Vermey M; van der Kwast T H; Romijn J C; Schröder F H
Immunocytochemical characterization of explant cultures of human prostatic stromal cells.
The Prostate 1995;27(1):42-9.
1995: Bangma C H; Kirkels W J; Chadha S; Schröder F H
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma.
The Journal of urology 1995;153(5):1635-6.
1995: Bosch J L; Hop W C; Kirkels W J; Schröder F H
The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume.
British journal of urology 1995;75(5):622-30.
1995: de Bruijn W C; Boevé E R; van Run P R; van Miert P P; de Water R; Romijn J C; Verkoelen C F; Cao L C; Schröder F H
Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation?
Scanning microscopy 1995;9(1):103-14.
1995: Kooistra A; König J J; Keizer D M; Romijn J C; Schröder F H
Inhibition of prostatic epithelial cell proliferation by a factor secreted specifically by prostatic stromal cells.
The Prostate 1995;26(3):123-32.
1995: Bosch J L; Kranse R; van Mastrigt R; Schröder F H
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism.
The Journal of urology 1995;153(3 Pt 1):689-93.
1995: Mickisch G H; Noordzij M A; vd Gaast A; Gebreamlack P; Köhrmann K U; Mogler-Drautz E; Kupper H; Schröder F H
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Journal of cancer research and clinical oncology 1995;121 Suppl 3():R11-6.
1995: Bangma C H; Hengeveld E J; Niemer A Q; Schröder F H
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population.
Ultrasound in medicine & biology 1995;21(1):11-6.
1995: Noordzij M A; van Steenbrugge G J; van der Kwast T H; Schröder F H
Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.
Urological research 1995;22(6):333-41.
1995: Bangma C H; Grobbee D E; Schröder F H
Volume adjustment for intermediate prostate-specific antigen values in a screening population.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):12-4.
1994: König J J; Teubel W; van Dongen J W; Romijn J C; Hagemeijer A; Schröder F H
Loss and gain of chromosomes 1, 18, and Y in prostate cancer.
The Prostate 1994;25(6):281-91.
1994: Vergunst H; Brakel K; Nijs H G; Laméris J S; Ten Kate F J; Schröder F H; Terpstra O T
Methyl tert-butyl ether improves the efficacy of extracorporeal shock wave lithotripsy of human gallstones implanted in pigs.
The European journal of surgery = Acta chirurgica 1994;160(11):619-25.
1994: Bosch J L; Hop W C; Niemer A Q; Bangma C H; Kirkels W J; Schröder F H
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old.
The Journal of urology 1994;152(5 Pt 1):1501-5.
1994: Nooter R I; Bosch J L; Schröder F H
Peyronie's disease and congenital penile curvature: long-term results of operative treatment with the plication procedure.
British journal of urology 1994;74(4):497-500.
1994: Bosch J L; Groen J; Schröder F H
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms.
Urology 1994;44(4):507-11.
1994: Boevé E R; Cao L C; De Bruijn W C; Robertson W G; Romijn J C; Schröder F H
Zeta potential distribution on calcium oxalate crystal and Tamm-Horsfall protein surface analyzed with Doppler electrophoretic light scattering.
The Journal of urology 1994;152(2 Pt 1):531-6.
1994: Schröder F H
5 alpha-reductase inhibitors and prostatic disease.
Clinical endocrinology 1994;41(2):139-47.
1994: Bangma C H; Blijenberg B G; Schröder F H
[Variability of values of prostate-specific antigen determined with 6 methods]
Nederlands tijdschrift voor geneeskunde 1994;138(16):813-7.
1994: Ruizeveld de Winter J A; Janssen P J; Sleddens H M; Verleun-Mooijman M C; Trapman J; Brinkmann A O; Santerse A B; Schröder F H; van der Kwast T H
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.
The American journal of pathology 1994;144(4):735-46.
1994: van den Ouden D; Davidson P J; Hop W; Schröder F H
Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer.
The Journal of urology 1994;151(3):646-51.
1994: Boevé E R; Cao L C; Verkoelen C F; Romijn J C; de Bruijn W C; Schröder F H
Glycosaminoglycans and other sulphated polysaccharides in calculogenesis of urinary stones.
World journal of urology 1994;12(1):43-8.
1994: de Bruijn W C; Boevé E R; van Run P R; van Miert P P; Romijn J C; Verkoelen C F; Cao L C; Schröder F H
Etiology of experimental calcium oxalate monohydrate nephrolithiasis in rats.
Scanning microscopy 1994;8(3):541-9; discussion 549-50.
1994: Bosch J L; Niemer A Q; Kirkels W J; Schröder F H
Signs and symptoms of benign prostatic hyperplasia in men screened for prostatic carcinoma.
Progress in clinical and biological research 1994;386():97-107.
1994: Schröder F H
Medical treatment of benign prostatic hyperplasia: the effect of surgical or medical castration.
Progress in clinical and biological research 1994;386():191-6.
1993: Schröder F H
Cyproterone acetate--mechanism of action and clinical effectiveness in prostate cancer treatment.
Cancer 1993;72(12 Suppl):3810-5.
1993: Krijnen J L; Janssen P J; Ruizeveld de Winter J A; van Krimpen H; Schröder F H; van der Kwast T H
Do neuroendocrine cells in human prostate cancer express androgen receptor?
Histochemistry 1993;100(5):393-8.
1993: König J J; van Dongen J W; Schröder F H
Preferential loss of abnormal prostate carcinoma cells by collagenase treatment.
Cytometry 1993;14(7):805-10.
1993: van Dongen J J; Grossi F S; Bosman F T; Schröder F H
Quantitative and qualitative evaluation of renal injury induced by shock waves delivered with the Siemens C generator.
Journal of endourology / Endourological Society 1993;7(5):379-81.
1993: van den Ouden D; Bentvelsen F M; Boevé E R; Schröder F H
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression.
British journal of urology 1993;72(4):489-94.
1993: Cao L C; Boevé E R; de Bruijn W C; Robertson W G; Schröder F H
A review of new concepts in renal stone research.
Scanning microscopy 1993;7(3):1049-64; discussion 1064-5.
1993: Verkoelen C F; Romijn J C; de Bruijn W C; Boevé E R; Cao L C; Schröder F H
Absence of a transcellular oxalate transport mechanism in LLC-PK1 and MDCK cells cultured on porous supports.
Scanning microscopy 1993;7(3):1031-8; discussion 1038-40.
1993: König J J; Teubel W; van Dongen J W; Hagemeijer A; Romijn J C; Schröder F H
Tissue culture loss of aneuploid cells from carcinomas of the prostate.
Genes, chromosomes & cancer 1993;8(1):22-7.
1993: Vergunst H; Terpstra O T; Brakel K; Nijs H G; Laméris J S; ten Kate F J; Schröder F H
Biliary extracorporeal shockwave lithotripsy: short-term and long-term observations in an animal model.
Hepato-gastroenterology 1993;40(4):388-95.
1993: Bentvelsen F M; van den Ouden D; Schröder F H
Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer.
British journal of urology 1993;72(1):88-91.
1993: Schröder F H
Endocrine therapy for prostate cancer: recent developments and current status.
British journal of urology 1993;71(6):633-40.
1993: Vergunst H; Brakel K; Nijs H G; Matura E; Drexler J; Steen G; Schröder F H; Terpstra O T
Electromagnetic shock wave lithotripsy of gallbladder stones in vitro: the role of different stone characteristics and treatment variables.
The Journal of stone disease 1993;5(2):105-12.
1993: De Bruijn W C; Ketelaars G A; Boevé E R; Sorber C W; Cao L C; Schröder F H
Electron energy-loss spectroscopical and image analysis of experimentally induced rat microliths. II.
The Journal of urology 1993;149(4):900-5.
1993: Boevé E R; Ketelaars G A; Vermeij M; Cao L C; Schröder F H; De Bruijn W C
An ultrastructural study of experimentally induced microliths in rat proximal and distal tubules.
The Journal of urology 1993;149(4):893-9.
1993: Schröder F H; Damhuis R A
[vasectomy and prostatic cancer; elucidation and practical advice]
Nederlands tijdschrift voor geneeskunde 1993;137(10):485-6.
1993: van Weerden W M; Moerings E P; van Kreuningen A; de Jong F H; van Steenbrugge G J; Schröder F H
Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models.
Cell proliferation 1993;26(1):67-75.
1993: van Weerden W M; van Kreuningen A; Elissen N M; Vermeij M; de Jong F H; van Steenbrugge G J; Schröder F H
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice.
The Prostate 1993;23(2):149-64.
1993: Bentvelsen F M; Schröder F H
Modalities available for screening for prostate cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(6):804-11.
1993: Schröder F H; Boyle P
Screening for prostate cancer--necessity or nonsense?
European journal of cancer (Oxford, England : 1990) 1993;29A(5):656-61.
1992: Davits R J; Blom J H; Schröder F H
Surgical management of renal carcinoma with extensive involvement of the vena cava and right atrium.
British journal of urology 1992;70(6):591-3.
1992: van Weerden W M; van Kreuningen A; Elissen N M; de Jong F H; van Steenbrugge G J; Schröder F H
Effects of adrenal androgens on the transplantable human prostate tumor PC-82.
Endocrinology 1992;131(6):2909-13.
1992: Dik P; Blom J H; Schröder F H
Mitomycin C and aminoglutethimide in the treatment of metastatic prostatic cancer: a phase II study.
British journal of urology 1992;70(5):542-5.
1992: Cao L C; Boevé E R; Schröder F H; Robertson W G; Ketelaars G A; de Bruijn W C
The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration.
The Journal of urology 1992;147(6):1643-6.
1992: Sneller Z W; Hop W C; Carpentier P J; Schröder F H
Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study.
The Journal of urology 1992;147(3 Pt 2):962-6.
1992: Zhao X; van Steenbrugge G J; Schröder F H
Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
Urological research 1992;20(3):193-7.
1992: Blom J H; Schröder F H
On the management of metastatic prostate cancer with LH-RH analogs.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1992;124():33-41.
1992: Grossi F S; Zhao X; Romijn J C; ten Kate F J; Schröder F H
Metastatic potential of human renal cell carcinoma: experimental model using subrenal capsule implantation in athymic nude mice.
Urological research 1992;20(4):303-6.
1992: van Weerden W M; Bierings H G; van Steenbrugge G J; de Jong F H; Schröder F H
Adrenal glands of mouse and rat do not synthesize androgens.
Life sciences 1992;50(12):857-61.
1992: Grossi F S; Keizer D M; Saracino G A; Erkens S; Romijn J C; Schröder F H
Flow cytometric analysis and motility response to laminin and fibronectin of four new metastatic variants of the human renal cell carcinoma line RC43.
Progress in clinical and biological research 1992;378():195-205.
1992: Blom J H; Schröder F H; Hammond B; Sylvester R
Radical nephrectomy with and without lymph node dissection: preliminary results of EORTC Protocol 30881. The EORTC Genitourinary Group.
Progress in clinical and biological research 1992;378():161-7.
1991: den Toom R; Nijs H G; van Blankenstein M; Schröder F H; Jeekel J; Terpstra O T
Extracorporeal shock wave lithotripsy of pancreatic duct stones.
The American journal of gastroenterology 1991;86(8):1033-6.
1991: den Toom R; Nijs H G; van Blankenstein M; Laméris J S; Schröder F H; Terpstra O T
Extracorporeal shock wave treatment of common bile duct stones: experience with two different lithotriptors at a single institution.
The British journal of surgery 1991;78(7):809-13.
1991: Kooistra A; König J J; Romijn J C; Schröder F H
Negative control of epithelial cell proliferation by prostatic stroma.
Anticancer research 1991;11(4):1495-500.
1991: van Weerden W M; van Steenbrugge G J; van Kreuningen A; Moerings E P; de Jong F H; Schröder F H
Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice.
The Journal of urology 1991;145(3):631-4.
1991: Oomens E H; van Steenbrugge G J; van der Kwast T H; Schröder F H
Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma.
The Journal of urology 1991;145(1):81-5.
1991: Schröder F H
Adjuvant endocrine treatment in early prostatic cancer.
Acta oncologica (Stockholm, Sweden) 1991;30(2):255-8.
1991: van Steenbrugge G J; van Uffelen C J; Bolt J; Schröder F H
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.
The Journal of steroid biochemistry and molecular biology 1991;40(1-3):207-14.
1991: Vekemans K M; Schröder F H
Prosthetic replacement of the inferior vena cava in renal cell carcinoma surgery.
European urology 1991;19(3):262-6.
1991: Schröder F H
Endocrine therapy: where do we stand and where are we going?
Cancer surveys 1991;11():177-94.
1991: van Weerden W M; van Kreuningen A; Moerings E P; de Jong F H; van Steenbrugge G J; Schröder F H
Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.
Urological research 1991;19(1):1-5.
1991: Schröder F H
Changing approaches in the treatment of benign prostatic hyperplasia.
European urology 1991;20 Suppl 1():63-7.
1990: van Weerden W M; van Steenbrugge G J; van Kreuningen A; Moerings E P; De Jong F H; Schröder F H
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice.
The Journal of steroid biochemistry and molecular biology 1990;37(6):903-7.
1990: Vergunst H; Terpstra O T; Schröder F H; Matura E
In vivo assessment of shock-wave pressures. Implication for biliary lithotripsy.
Gastroenterology 1990;99(5):1467-74.
1990: Bentvelsen F M; Bogdanowicz J F; Oosterom R; Schröder F H
[A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma]
Nederlands tijdschrift voor geneeskunde 1990;134(33):1596-600.
1990: Bosch R; Schröder F H
Radical prostatectomy and adjuvant endocrine treatment: a review.
Progress in clinical and biological research 1990;359():239-47; discussion 249-50.
1990: Jansen H; Gallee M P; Schröder F H
Analysis of sonographic pattern in prostatic cancer: comparison of longitudinal and transversal transrectal ultrasound with subsequent radical prostatectomy specimens.
European urology 1990;18(3):174-8.
1990: Schröder F H
EORTC Genitourinary Group: prostate cancer studies.
Progress in clinical and biological research 1990;357():73-81.
1990: Schröder F H
What is new in endocrine therapy of prostatic cancer?
Progress in clinical and biological research 1990;357():45-52.
1990: Schröder F H
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Progress in clinical and biological research 1990;359():93-103; discussion 105-7.
1990: Schröder F H
Antiandrogenic substances in the management of prostatic cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1990;118():163-73.
1989: Vergunst H; Terpstra O T; Brakel K; Laméris J S; van Blankenstein M; Schröder F H
Extracorporeal shockwave lithotripsy of gallstones. Possibilities and limitations.
Annals of surgery 1989;210(5):565-75.
1989: Ackaert K S; Dik P; Lock M T; Kurth K H; Schröder F H
Treatment of distal ureteral stones in the horse riding position.
The Journal of urology 1989;142(4):955-7.
1989: van Dongen J W; van Steenbrugge G J; Romijn J C; Schröder F H
The cytocidal effect of high energy shock waves on human prostatic tumour cell lines.
European journal of cancer & clinical oncology 1989;25(8):1173-9.
1989: Nijman R J; Ackaert K; Scholtmeijer R J; Lock T W; Schröder F H
Long-term results of extracorporeal shock wave lithotripsy in children.
The Journal of urology 1989;142(2 Pt 2):609-11; discussion 619.
1989: Schröder F H
Can prostatectomy add any benefit to the hormonal treatment of stage C prostatic carcinoma?
Progress in clinical and biological research 1989;303():241-52.
1989: Ackaert K S; Hop W C; Heemskerk C A; Schröder F H
Risk factors in outpatient extracorporeal shock wave lithotripsy.
European urology 1989;16(5):349-53.
1989: van Aubel O G; Bolt-de Vries J; Blankenstein M A; de Jong F H; Schröder F H
Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy.
Urological research 1989;17(2):99-102.
1989: König J J; Kamst E; Hagemeijer A; Romijn J C; Horoszewicz J; Schröder F H
Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.
Urological research 1989;17(2):79-86.
1989: Schröder F H
Early versus delayed endocrine treatment in metastatic prostatic cancer.
Progress in clinical and biological research 1989;303():253-60.
1989: Ackaert K S; Schröder F H
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review.
Urological research 1989;17(1):3-7.
1989: Blom J H; Hirdes W H; Schröder F H; de Jong F H; Kwekkeboom D J; van't Veen A J; Sandow J; Krauss B
Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
Urological research 1989;17(1):43-6.
1989: Oosterom R; Bogdanowicz J; Schröder F H
Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
European urology 1989;16(4):253-7.
1988: Schröder F H; Cooper E H; Debruyne F M; Denis L; Newling D W; Pavone-Macaluso M; Smith P H; Sylvester R
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group.
British journal of urology 1988;62(6):502-10.
1988: Vergunst H; Terpstra O T; Brakel K; Laméris J S; van Blankenstein M; Schröder F H
[Extracorporeal shockwave lithotripsy in the treatment of gallbladder stones]
Nederlands tijdschrift voor geneeskunde 1988;132(43):1965-70.
1988: König J J; Hagemeijer A; Smit B; Kamst E; Romijn J C; Schröder F H
Cytogenetic characterization of an established xenografted prostatic adenocarcinoma cell line (PC-82).
Cancer genetics and cytogenetics 1988;34(1):91-9.
1988: Schröder F H
Current concepts in the management of prostatic cancer.
American journal of clinical oncology 1988;11 Suppl 1():S1-5.
1988: van Aubel O; Bolt-de Vries J; Blankenstein M A; Schröder F H
Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer.
The Prostate 1988;12(3):191-8.
1988: van Steenbrugge G J; Groen M; van Kreuningen A; de Jong F H; Gallee M P; Schröder F H
Transplantable human prostatic carcinoma (PC-82) in athymic nude mice. III. Effects of estrogens on the growth of the tumor tissue.
The Prostate 1988;12(2):157-71.
1988: van Steenbrugge G J; Bolt-de Vries J; Blankenstein M A; Brinkmann A O; Schröder F H
Transplantable human prostatic carcinoma (PC-82) in athymic nude mice. II. Tumor growth and androgen receptors.
The Prostate 1988;12(2):145-56.
1988: van Steenbrugge G J; Schröder F H
Androgen-dependent human prostate cancer in nude mice. The PC-82 tumor model.
American journal of clinical oncology 1988;11 Suppl 2():S8-12.
1985: Oishi K; Okada K; Yoshida O; Romijn J C; Bolt de Vries J; Schröder F H
[Androgen receptor and 5 alpha-reductase activity in the epithelium and the stroma of human benign prostatic hyperplasia]
Hinyokika kiyo. Acta urologica Japonica 1985;31(5):785-90.
1985: van Aubel O G; Bolt-de Vries J; Blankenstein M A; ten Kate F J; Schröder F H
Nuclear androgen receptor content in biopsy specimens from histologically normal, hyperplastic, and cancerous human prostatic tissue.
The Prostate 1985;6(2):185-94.
1984: van Steenbrugge G J; Groen M; Romijn J C; Schröder F H
Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82).
The Journal of urology 1984;131(4):812-7.
1983: Van Steenbrugge G J; Blankenstein M A; Bolt-de Vries J; Romijn J C; Schröder F H; Vihko P
Effect of hormone treatment on prostatic acid phosphatase in a serially transplantable human prostatic adenocarcinoma (PC-82).
The Journal of urology 1983;129(3):630-3.
1981: Foekens J A; Bolt-de Vries J; Mulder E; Blankenstein M A; Schröder F H; van der Molen H J
Nuclear androgen receptors in human prostatic tissue. Extraction with heparin and estimation of the number of binding sites with different methods.
Clinica chimica acta; international journal of clinical chemistry 1981;109(1):91-102.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Fritz Schröder

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Geographic Areas

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Fritz Schröder (preview)

All Publications